Issuu

Iodixanol Injection, USP

First FDA-approved, cost-effective generic that is fully substitutable to Visipaque®.*

WARNING: NOT FOR INTRATHECAL USE

Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema.

Please see Important Safety Information on next page.

• AP Rated

• Iso-Osmolar

• Dimeric

• Preservative Free

• Polymer Bottle LEARN MORE

Explore Available Contrast Agents GenericContrastAgents.com

IMPORTANT SAFETY INFORMATION

WARNING: NOT FOR INTRATHECAL USE

Contraindications: Iodixanol Injection is contraindicated for intrathecal use.

Warnings and Precautions:

Hypersensitivity Reactions: Life-threatening or fatal reactions can occur. Most severe reactions develop shortly after the start of the injection, but reactions can occur up to hours later. Always have emergency equipment and trained personnel available.

Contrast-Induced Acute Kidney Injury: Acute injury including renal failure can occur. Minimize dose and maintain adequate hydration to minimize risk.

Cardiovascular Adverse Reactions: Life-threatening or fatal cardiovascular reactions, including hypotension, shock, and cardiac arrest have occurred with the use of Iodixanol. Most deaths occur during injection or five to ten minutes later, with cardiovascular disease as the main aggravating factor. Use the lowest necessary dose of Iodixanol in patients with congestive heart failure.

Thromboembolic Events: Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke can occur during angiocardiography procedures with both ionic and nonionic contrast agents.

Extravasation and Injection Site Reactions: Extravasation of Iodixanol injection may cause tissue necrosis and/or compartment syndrome, particularly in patients with severe arterial or venous disease. Ensure intravascular placement of catheters prior to injection.

Thyroid Storm in Patients with Hyperthyroidism: Thyroid storm has occurred after the intravascular use of iodinated contrast agents in patients with hyperthyroidism, or with an autonomously functioning thyroid nodule.

Thyroid Dysfunction in Pediatric Patients 0 to 3 Years of Age:

Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression has been reported after both single exposure and multiple exposures to iodinated contrast media in patients 0 to 3 years of age. After exposure to iodinated contrast media, individualize thyroid function monitoring based on underlying risk factors, especially in term and preterm neonates.

Hypertensive Crisis in Patients with Pheochromocytoma: Hypertensive crisis has occurred after the use of iodinated contrast agents in patients with pheochromocytoma. Inject the minimum amount of contrast necessary, assess the blood pressure throughout the procedure, and have measures for treatment of a hypertensive crisis readily available.

Sickle Cell Crisis in Patients with Sickle Cell Disease: Iodinated contrast agents when administered intravascularly may promote sickling in individuals who are homozygous for sickle cell disease.

Severe Cutaneous Adverse Reactions: Severe cutaneous adverse reactions (SCAR) may develop from one hour to several weeks after intravascular contrast agent administration. These reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS). Avoid administering iodixanol to patients with a history of a severe cutaneous adverse reaction to iodixanol.

Adverse Events: Serious, life-threatening, and fatal reactions, mostly of cardiovascular origin, have been associated with the administration of iodine-containing contrast agents, including Iodixanol Injection. Most common adverse reactions (incidence greater than 0.5%) in adult patients after iodixanol injection: Discomfort, warmth, pain; Cardiovascular: angina. Gastrointestinal: diarrhea, nausea, vomiting. Nervous System: agitation, anxiety, insomnia, nervousness, dizziness, headache, migraine, unusual skin sensations, sensory disturbance, fainting, sensation of spinning. Skin: itchy rash, severe itching, hives. Special Senses: Smell, taste, and vision alteration. Pediatric patients experienced similar adverse reactions.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

Lactation: A lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk for 10 hours after iodixanol administration in order to minimize drug exposure to a breast fed infant.

Pediatric Use: Pediatric patients at high risk of adverse reactions during and after administration of contrast agents include those with asthma, hypersensitivity to other medication and/or allergens, cyanotic and acyanotic heart disease, chronic heart failure, or a serum creatinine >1.5 mg/dL. Patients with immature renal function or dehydration may be at increased risk due to prolonged elimination of iodinated contrast agents.

Geriatric Use: Dose selection for an elderly patient should be cautious usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.

INDICATIONS AND USAGE

Iodixanol injection is a radiographic contrast agent indicated for the following:

Intra-arterial Procedures

Adults and pediatric patients 12 years of age and over

• Intra-arterial digital subtraction angiography (270 mg Iodine/mL and 320 mg Iodine/mL).

• Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg Iodine/mL).

Pediatric patients less than 12 years of age

• Angiocardiography, cerebral arteriography, and visceral arteriography (320 mg Iodine/mL).

Intravenous Procedures

Adults and pediatric patients 12 years of age and over Computed tomography (CT) imaging head and body (270 mg Iodine/mL and 320 mg Iodine/mL).

• Excretory urography (270 mg Iodine/mL and 320 mg Iodine/mL).

• Peripheral venography (270 mg Iodine/mL).

• Coronary computed tomography angiography (CCTA) to assist diagnostic evaluation of patients with suspected coronary artery disease (320 mg Iodine/mL).

Pediatric patients less than 12 years of age

• CT imaging of the head and body (270 mg Iodine/mL).

• Excretory urography (270 mg Iodine/mL).

This Important Safety Information does not include all the information needed to use Iodixanol Injection, USP safely and effectively. Please see full prescribing information, including BOXED WARNING, for Iodixanol Injection, USP. Full prescribing information is also available at at www.fresenius-kabi.com/us

Gadobutrol Injection

Providing a cost-effective MR contrast option that’s fully substitutable to Gadavist ® . *

• FDA-approved, AP Rated

• High Relaxivity 1,2

• Macrocyclic Bond 1,2

• High Concentration GBCA 1,2

• Preservative Free 1,2

• The container closure is not made with natural rubber latex

• Bioequivalent and fully substitutable to Gadavist ®*

LEARN MORE

Explore Available Contrast Agents GenericContrastAgents.com

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS

Risk Associated with Intrathecal Use

Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Gadobutrol injection is not approved for intrathecal use.

Nephrogenic Systemic Fibrosis

GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of gadobutrol injection in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

• The risk for NSF appears highest among patients with:

o Chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), or

o Acute kidney injury.

• Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (for example, age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.

• For patients at highest risk for NSF, do not exceed the recommended gadobutrol injection dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.

IMPORTANT SAFETY INFORMATION

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS

Risk Associated with Intrathecal Use

Nephrogenic Systemic Fibrosis

• The risk for NSF appears highest among patients with:

o Chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), or

o Acute kidney injury.

CONTRAINDICATIONS

Gadobutrol Injection is contraindicated in patients with history of severe hypersensitivity reactions to Gadobutrol Injection.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory, or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred following gadobutrol administration. Before gadobutrol administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to gadobutrol. Monitor patients closely during and after administration of gadobutrol.

Acute Respiratory Distress Syndrome (ARDS): ARDS has been reported in patients administered gadobutrol injection and may be characterized by severe hypoxemia requiring oxygen support and mechanical ventilation. Onset can occur within <30 minutes to 24 hours after administration. For Patients demonstrating respiratory distress after administration, assess oxygen requirement and monitor for worsening respiratory function.

Gadolinium Retention: Gadolinium is retained for months or years in brain, bone, and other organs. Linear GBCAs cause more retention than macrocyclic GBCAs. At equivalent doses, retention varies among the linear agents. Retention is lowest and similar among the macrocyclic GBCAs. Consequences of gadolinium retention in the brain have not been established, but they have been established in the skin and other organs in patients with impaired renal function. While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Consider the retention characteristics of the agent and minimize repetitive GBCA studies, when possible.

Acute Kidney Injury: In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of GBCAs. Do not exceed the recommended dose; the risk of acute kidney injury may increase with higher than recommended doses.

Extravasation and Injection Site Reactions: Ensure catheter and venous patency before the injection of gadobutrol. Extravasation into tissues during gadobutrol administration may result in moderate irritation.

Overestimation of Extent of Malignant Disease in MRI of the Breast: Gadobutrol MRI of the breast overestimated the histologically confirmed extent of malignancy in the diseased breast in up to 50% of the patients.

Low Sensitivity for Significant Arterial Stenosis: The performance of gadobutrol MRA for detecting arterial segments with significant stenosis (>50% renal, >70% supra-aortic) has not been shown to exceed 55%. Therefore, a negative MRA study alone should not be used to rule out significant stenosis.

ADVERSE EVENTS

The most common adverse reactions (incidence >_ 0.5%) associated with gadobutrol are headache (1.7%), nausea (1.2%) and dizziness (0.5%).

The following additional adverse reactions have been identified during post marketing use of gadobutrol or other GBCAs:

• Cardiac arrest

• Nephrogenic Systemic Fibrosis (NSF)

• Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor).

• Respiratory, Thoracic, and Mediastinal Disorders: Acute respiratory distress syndrome, pulmonary edema.

• General Disorders and Administration Site Conditions: Adverse reactions with variable onset and duration have been reported after GBCA administration. These include fatigue, asthenia, pain syndromes, and heterogeneous clusters of symptoms in the neurological, cutaneous, and musculoskeletal systems.

• Skin: Gadolinium associated plaques.

• Gastrointestinal Disorders: Acute pancreatitis with onset within 48 hours after GBCA administration

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

USE IN SPECIFIC POPULATIONS

Pregnancy: GBCAs cross the placenta and result in fetal exposure and gadolinium retention. Because of the potential risks of gadolinium to the fetus, use gadobutrol only if imaging is essential during pregnancy and cannot be delayed.

INDICATIONS AND USAGE

Gadobutrol Injection is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI):

• To detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients (including term neonates).

• To assess the presence and extent of malignant breast disease in adult patients.

• To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD).

Gadobutrol Injection is indicated for use in magnetic resonance angiography (MRA):

• To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients, including term neonates.

This Important Safety Information does not include all the information needed to use Gadobutrol Injection safely and effectively. Please see full prescribing information, including BOXED WARNING, for Gadobutrol Injection Single-Dose Vials and Imaging Bulk Package at www.fresenius-kabi.com/us

Fresenius Kabi has expanded access to affordable generic contrast agents, allowing the radiology community the opportunity to diversify manufacturers. It’s good to know you have another choice.

By partnering with Fresenius Kabi, you will have access to the same safe and effective contrast agents you have always relied on – at a lower cost. That’s how Fresenius Kabi brings confidence within reach. Now you have a choice! Explore Available Contrast Agents.

Workforce issues, theranostics take center stage for Minnies 2025

The Minnies Expert Panel has spoken. After two competitive rounds of voting on over 100 nominees in 15 categories, the winners have been selected for the 2025 edition of the Minnies, our annual awards program recognizing excellence in radiology.

This year, issues impacting the radiology workforce and theranostics feature prominently. Minnies 2025 recipients include a few previous trophy winners, as well as several first-timers. We’ve also once again invited winners to say a few words about their award, and we hope you enjoy our article as well as the opportunity to hear directly from the recipients.

Congratulations to all the winners of the 2025 Minnies awards, and also to the runners-up and the hundreds of candidates who made the semifinalist list and finalist list.

Interested in the history of the Minnies? You can view our comprehensive list of all the Minnies winners over the past 25 years.

Most Influential Radiology Researcher

Minnies 2025 Winner: Eric

Christensen, PhD, Harvey L. Neiman Health Policy Institute

Eric Christensen, PhD

“I approach problems within the framework of the question of what we would expect a population to do in response to the economics of the situation,” he said. “How does it play out? The fact is, economic incentives influence people whether they’re aware of them or not.”

Christensen has been with the Harvey L. Neiman Health Policy Institute (HPI) since 2021, and although he has specialized in healthcare economics throughout his career, the focus on radiology is new. His work experience has included conducting interdisciplinary research at the Center for Naval Analyses’ Institute for

Public Research in Arlington, VA; serving on the Health Services Management faculty at the University of Minnesota College of Continuing & Professional Studies in Minneapolis; and conducting health economic research at Children’s Hospitals and Clinics of Minnesota, also in Minneapolis (to name just a few).

“Radiology has its own unique issues,” he said. “For example, many healthcare models assume a face-to-face doctor/patient relationship, but this is not necessarily the case for radiology. Because not all physicians are the same, the approach should reflect that.”

He and his colleagues regularly interview experts about trends in radiology and follow legislative changes. In the past few years, his team has published studies about Black women’s access to new mammography technology, rates of nonradiologists’ interpretation of office-based imaging, potential causes of a future radiology workforce shortage, the financial effects of the No Surprises Act, and how imaging studies interpreted by nonphysician practitioners are often repeated. Currently, he’s working on research regarding workforce concerns such as attrition and turnover, Medicare reimbursement and its association with healthcare disparities, and procedural complexity for interventional radiologists.

“In the future, we’d like to do more to explore the value of radiology in terms of its impact on patient care -- particularly as it relates to radiologists’ role in reducing low-value imaging -- and of course to track what’s coming next in the field so we can inform health policy discussions,” he said.

Christensen Minnies Award Acceptance

Most Effective Radiology Educator

Minnies 2025 Winner: Lea Alhilali, MD, Arizona State Shufeldt School of Medicine and Medical Engineering

First-time Minnies winner Lea Alhilali, MD, pivoted to education after years of engaging in “traditional academics” at Harvard Medical School, UT Southwestern Medical Center, Barrow, and the University of Pittsburgh.

Part of her shift was prompted by her term as program director of Barrow’s neuroradiology fellowship, during which she learned via feedback from her students to use social media for teaching. Her efforts in this regard have taken off: On X and Instagram, she has 67,000 and 105,000 followers, respectively.

“I assumed social media was for posting cute pictures of my kids for my friends,” she said. “Initially, it didn’t occur to me that social media could be a way to teach. But the new generation of doctors I teach use social media as a matter of course, so I posted some of my lectures and found that they got some good notice.”

At Arizona State, Alhilali is part of the team working to establish a radiology department at the new medical school there. She is also in charge of the school’s medical student rotation program. In addition to her teaching duties, Alhilali is active in the academic journal arena, serving as senior editor for education for the American Journal of Neurology, associate editor of social media and digital innovation for Radiographics, and deputy editor for Clinical Neuroimaging As well, the open-access radiology resource Radiopaedia.org hosts a page with links to her lectures.

Alhilali finds being an educator deeply satisfying. She has lectured around the world to audiences that include medical students, residents, attendings, vendors, and representatives from imaging firms; recently, she donated more than 100 of her recorded talks to Mount Kilimanjaro Medical Center in Tanzania, a facility that does not have a full-time neuroradiologist available. “There’s an incredible demand for radiology education that is understandable and can be communicated in fresh ways,” she said. “As radiologists, we can use social media to put out reliable, accurate content.”

Lea Alhilali, MD

Most Effective Radiologic Sciences Educator

Minnies 2025 Winner: Jennifer Thompson, Austin Peay State University, Clarksville, TN

Jennifer Thompson’s move from New Mexico to Austin Peay State University in Clarksville, TN, opened the door that led to her 2025 Minnies win for Most Effective Radiologic Sciences Educator. It’s a role she takes to heart. As a professor and radiologic science program director at Austin Peay, Thompson creates educational and advocacy opportunities for students through her tutoring, advising, research, speaking engagements, capital visits, recruitment, and volunteering with the Tennessee Society of Radiologic Technologists (TSRT), which includes the annual meeting for which she plays a key role in the meeting’s development.

Professional development is a requirement for Thompson’s students through the American Society of Radiologic Technologists, including attending the annual meeting.

“I am invited for speaking engagements around the country, and I invite my students to speak with me because I have to give them the ability to learn how to advocate for themselves and to teach others,” she said. “I use my platform to give them one.”

Thompson also collaborates with other healthcare programs to create interprofessional simulations that stage patient journeys. These simulations offer students the opportunity to interact with and advocate for other professionals, including medical laboratory scientists, nurses, and others. Students discuss their roles as radiologic technologists and progression to other roles, such as radiologist assistant.

“This is so we can put together our scopes of practice and make it all make sense as they’re in clinic,” she said.

Thompson gamifies classroom lessons, too. For example, she has created a unique anatomical relationship matching game and has repurposed board games such as Candy Land to keep students highly engaged.

Jennifer Thompson

“Students are learning to think critically when we create our own rules rather than using the textbook,” she said. “This is a crucial step in becoming an imaging professional.”

Interest in Austin Peay’s radiologic science program is flourishing, according to Thompson, who has facilitated expanding the curriculum with new affiliation agreements.

“I am truly humbled by this recognition and profoundly grateful to be acknowledged for contributing to the educational journey of our students at APSU, as well as to the broader professional community across the United States,” Thompson said in an APSU blog post

Thompson has been director of the Austin Peay State University Radiologic Sciences Program since 2018.

“It’s taken a lot of determination to get me to this point,” she said. “Myself, my kids pushing me, and love of the profession. As an educator, I miss my daily interactions with patients, but I would never be able to give back to the community as much as I can now.”

Most Significant News Event in Radiology

Minnies 2025 Winner: Impact of NIH funding cuts on medical imaging research community

The U.S. government has been in shutdown since October 1, and since the stoppage affects the federal budget, the level of cuts to the U.S. National Institutes of Health (NIH) that could be enforced remains unclear -- which has been causing consternation among medical imaging researchers.

Professional imaging organizations have been tracking potential cuts to the NIH at least since March, when the institute announced that grants and funding policies and processes were “evolving” as the NIH aligned with “new agency priorities.”

The news had an immediate effect on radiology, as researchers and policy experts sought to navigate the changed landscape. By May, academic radiology researchers continued to grapple with the “coming new normal” after the NIH’s apparent $18 billion funding cut to health research spending.

As of May 6, the Association of American Medical Colleges estimated NIH grant terminations would be $1.9 billion for all U.S. institutions combined, and just over $1 billion for medical schools and hospitals. At the end of that month, President Trump released a full federal fiscal year 2026 budget; in a June 4 statement, the American College of Radiology (ACR) warned that the proposed budget included a cut to the NIH of approximately $18 billion compared with 2025 levels, and it vowed to continue advocating for increased NIH and Advanced Research Projects Agency for Health (ARPA-H) funding.

In September, appropriations bills made the rounds in Congress. One advanced by the U.S. House Committee on Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies (Labor-HHS) provided $48 billion for the NIH and included funding for all 27 NIH institutes and centers, and did not implement President Donald Trump’s budget request to cut NIH funding to $27.5 billion. The Senate Committee on Appropriations’ version of the bill proposed NIH funding of $48.7 billion.

Both bills remain unresolved. AuntMinnie will continue to monitor the government’s shutdown status and legislation that will affect the NIH’s funding.

Biggest Threat to Radiology

Minnies 2025 Winner: Radiology workforce shortage

For the third year in a row, our expert panel recognized workforce shortages as the biggest threat to radiology, with recent reports all but confirming these concerns.

Studies published in 2025 found that about two out of three academic and hospital radiology practices reported being understaffed, and nearly half of radiologists in a separate survey reported workforce shortages as their top concern. The same survey also found that pediatric radiology continues to experience a major shortage. And if no efforts are made, the current supply of radiologists in the U.S. and increased demand for imaging are projected to lead to a continued workforce shortage.

As for radiologic technologists, the American Society of Radiologic Technologists in July reported that employee vacancy rates increased for CT, MRI, and bone densitometry, with CT reaching an all-time high.

Experts told AuntMinnie that these shortages may stem from job candidates disagreeing on salary expectations, poor communication, a competitive job market, and more emphasis on work-life balance.

Workforce shortages also create more problems for practices, including increased risk of burnout for staff and delays in patient care. However, leaders in radiology, radiologic technology, and radiation oncology are taking action and showing their resilience and adaptability.

The ASRT, the American College of Radiology, the Society of Diagnostic Medical Sonography, the Society of Nuclear Medicine and Molecular Imaging, and other societies have created a joint workforce action plan that aims to raise awareness of multiple roles within radiology and radiation oncology.

Can AI help? Experts believe it could enable significant efficiency gains in a number of applications, such as streamlining the radiology reporting process. However, it will likely take more than just new technology to make meaningful progress on the radiology workforce shortage.

2025 ServiceTrak Winners:

Chemistry

(Announced at ADLM 2024)

Best Service: Roche

Best Customer Satisfaction: Roche

Best System Performance: Roche, QuidelOrtho

Immunoassay

(Announced at ADLM 2024)

Best Customer Satisfaction: Roche

Best Service: bioMérieux, Inc.

Best System Performance: bioMérieux, Inc.

Integrated Systems

(Announced at ADLM 2024)

Best Customer Satisfaction: Roche

Best System Performance: Roche, QuidelOrtho

Best Service: Roche, QuidelOrtho

Hematology

(Final Winners Added November 2025)

Best System Performance: Sysmex America, Inc.

Best Customer Satisfaction: Sysmex America, Inc.

Best Service: Sysmex America, Inc.

ID/AST

Best System Performance: bioMérieux, Inc.

Best Customer Satisfaction: bioMérieux, Inc.

Best Service: bioMérieux, Inc.; Beckman Coulter

Coagulation

Best System Performance: Siemens Healthineers; Werfen

Best Customer Satisfaction: Werfen

Best Service: Siemens Healthineers

Blood Culture

Best System Performance: bioMérieux, Inc.

Best Customer Satisfaction: bioMérieux, Inc.

Best Service: bioMérieux, Inc.; Becton Dickinson

Molecular Diagnostics

Best System Performance: Roche; bioMérieux, Inc.

Best Customer Satisfaction: Roche; Cepheid

Best Service: Roche